高级检索
当前位置: 首页 > 详情页

Phenotype versus genotype discordant rifampicin susceptibility testing in tuberculosis: implications for a diagnostic accuracy

文献详情

资源类型:
Pubmed体系:
机构: [1]National TB Control Program, National TB Reference Laboratory, Islamabad, Pakistan. [2]Department of Microbiology, Quaid-i-Azam University, Islamabad, Pakistan. [3]Zhongjing Research and Industrialization Institute of Chinese Medicine, Zhongguancun Scientific Park, Nanyang, Henan, China. [4]Institute of Molecular Biology and Biotechnology (IMBB), The University of Lahore, Lahore, Pakistan. [5]School of Medicine, Department of Immunology and Microbiology, Shanghai Jiao Tong University, Shanghai, China. [6]National Tuberculosis Clinical Lab of China, Beijing Chest Hospital, Capital Medical University, Beijing, China. [7]School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, China. [8]Peng Cheng Laboratory, Shenzhen, Guangdong, China. [9]Faculty of Medical Sciences, University College London, London, United Kingdom.
出处:

摘要:
An accurate diagnosis of drug resistance in clinical isolates is an important step for better treatment outcomes. The current study observed a higher discordance rate of rifampicin resistance on Mycobacteria Growth Indicator Tube (MGIT) drug susceptibility testing (DST) than Lowenstein-Jenson (LJ) DST when compared with the rpoB sequencing. We detected a few novel mutations and their combination in rifampicin resistance isolates that were missed by MGIT DST and may be useful for the better management of tuberculosis (TB) treatment outcomes. Few novel deletions in clinical isolates necessitate the importance of rpoB sequencing in large data sets in geographic-specific locations, especially high-burden countries. We explored the discordance rate on MGIT and LJ, which is important for the clinical management of rifampicin resistance to avoid the mistreatment of drug-resistant TB. Furthermore, MGIT-sensitive isolates may be subjected to molecular methods of diagnosis for further confirmation and treatment options.

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2022]版:
大类 | 1 区 生物学
小类 | 1 区 微生物学
最新[2025]版:
大类 | 2 区 生物学
小类 | 3 区 微生物学
第一作者:
第一作者机构: [1]National TB Control Program, National TB Reference Laboratory, Islamabad, Pakistan. [2]Department of Microbiology, Quaid-i-Azam University, Islamabad, Pakistan.
通讯作者:
通讯机构: [3]Zhongjing Research and Industrialization Institute of Chinese Medicine, Zhongguancun Scientific Park, Nanyang, Henan, China. [7]School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, China. [8]Peng Cheng Laboratory, Shenzhen, Guangdong, China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:2020 今日访问量:0 总访问量:646 更新日期:2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持:重庆聚合科技有限公司 地址:广州市越秀区大德路111号